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INTRODUCTION
Urinary incontinence (UI) can affect up to 50% of women worldwide.1 This rate can reach 
77% among elderly women living in nursing homes.2 Additionally, recent research showed 
that 37.5% of younger women (from 30 to 50 years) in a primary care setting complained of 
stress incontinence.3  
Urinary incontinence can be classified into three main types: stress, urge and overflow incon-
tinence. Many women have mixed characteristics of more than one type.4-6 Identifying the classi-
fication can be useful for making decisions regarding therapy, since different therapeutic options 
are available for each type.7
Women presenting stress incontinence (the most common type in younger women) have 
involuntary leakage of urine relating to increased intra-abdominal pressure (e.g. during physical 
exercises, sneezing, coughing or laughing) in the absence of a bladder contraction.4 Urge incon-
tinence (or “overactive bladder with incontinence”) is characterized by the urge to void immedi-
ately, preceding or accompanied by involuntary loss of urine, which can range from a few drops 
to full wetting of underwear.4 It is more common among elderly women and it is related to other 
clinical situations such as infections or chronic conditions (e.g. neurological disorders or diabetes). 
Overflow incontinence is characterized by continuous urinary leakage or dripping in the presence 
of incomplete bladder emptying. Women with overflow incontinence complain of weak or inter-
mittent urinary stream, frequency, hesitancy and nocturia. When the bladder is full, stress leakage 
can occur or low-amplitude bladder contractions can be induced, thus leading to symptoms sim-
ilar to urge or stress incontinence. It is caused by bladder obstruction or detrusor hypoactivity.7 
Finally, women with mixed incontinence can present features of both stress and urge incontinence.4 
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ABSTRACT
BACKGROUND: Urinary incontinence is a highly prevalent condition that impacts self-esteem and over-
all quality of life. Many non-surgical treatment options are available, ranging from pharmacological ap-
proaches to pelvic exercises. We aimed to summarize the available evidence regarding these non-surgi-
cal interventions.
DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based 
Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM-UNIFESP). 
METHODS: A sensitive search was conducted to identify all Cochrane systematic reviews that fulfilled the 
inclusion criteria. Titles and abstracts were screened by two authors. 
RESULTS: We included 20 Cochrane systematic reviews: 4 assessing methods of vesical training, 3 evalu-
ating pharmacological interventions, 4 studying pelvic floor muscle training approaches and 9 aimed at 
other alternatives (such as urethral injections, weighted vaginal cone use, acupuncture, biostimulation 
and radiofrequency therapy). The reviews found that the evidence regarding the benefits of these diverse 
interventions ranged in quality from low to high. 
CONCLUSIONS: This review included 20 Cochrane systematic reviews that provided evidence (of diverse 
quality) for non-pharmacological interventions for patients with urinary incontinence. Moderate to high 
quality of evidence was found favoring the use of pelvic floor muscle training among women with urinary 
incontinence. To establish solid conclusions for all the other comparisons, further studies of good meth-
odological quality are needed.
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It is important to point out that despite the considerable prev-
alence of UI, it continues to be an underdiagnosed and an under-
treated disease: only about a quarter of women with complaints 
pursue medical care and, of those, less than 50% receive some type 
of treatment.8 Persistence of UI has been correlated with poor health 
outcomes comprising higher risk of urinary infections, sleep dis-
turbances, falls and fractures, and depression.9,10 
Because UI is a highly prevalent condition, with high impact on 
quality of life, several treatment options for it are currently available. 
These options range from pelvic exercises to surgical techniques, 
including pharmacological therapies and use of local devices. 
The aim of the present study was to identify and summarize 
the evidence from Cochrane systematic reviews (SRs) regarding 
non-surgical therapeutic options for preventing urinary inconti-
nence and for treating women with this condition.
METHODS
Design and setting
A review of Cochrane SRs was conducted within the Discipline 
of Evidence-based Medicine of Escola Paulista de Medicina, 
Universidade Federal de São Paulo (EPM-UNIFESP). This article 
was specifically developed for the section Cochrane Highlights, 
which is an initiative for disseminating Cochrane reviews. 
This  initiative results from a formal partnership between the 
São Paulo Medical Journal and Cochrane, and it is supported by 
Cochrane Brazil.
Inclusion criteria
Types of study
We included full Cochrane SRs published in the Cochrane 
Database of Systematic Reviews (CDSR). Protocols for SRs 
and withdrawn or outdated versions of SRs were not included. 
There was no limit on publication dates.
Types of participants
The participants considered were women who had been diag-
nosed with any type of urinary incontinence. We did not take 
into consideration reviews that included participants of both 
sexes but did not have any subgroup analyses that considered 
women alone.
Types of intervention
We considered SRs assessing any non-surgical therapeutic option, 
whether used in isolation or in combination with each other. 
Types of outcomes 
We considered any clinical or laboratory outcomes, as evaluated 
by the authors of the SRs included.
Search for reviews 
We conducted a systematic search in the Cochrane Database of 
Systematic Reviews (CDSR) (via Wiley) on October 18, 2017, 
sensitively using the MeSH term “urinary incontinence” and all 
related variants, in titles, abstracts and keywords. The detailed 
search strategy is presented in Table 1.
Selection of reviews 
The titles and abstracts were screened by two authors (RLP, AALFC 
or IMV) independently. The SRs that met the inclusion criteria were 
selected. Any disagreement was resolved by consulting a senior 
author (RR). 
Presentation of results
The results from the search and the SRs included were presented 
through a descriptive approach (qualitative synthesis).
RESULTS
Search results
Our search strategy retrieved 106 references and, after screening 
the titles and abstracts, 31 SRs were preselected. After assessing 
#1 MeSH descriptor: [Urinary Incontinence] explode all trees
#2 MeSH descriptor: [Urinary Incontinence, Stress] explode all trees
#3 MeSH descriptor: [Urinary Incontinence, Urge] explode all trees
#4 MeSH descriptor: [Urinary Bladder, Overactive] explode all trees
#5 MeSH descriptor: [Urinary Bladder, Neurogenic] explode all trees
#6 (Urinary Incontinence) or (Incontinence, Urinary) or (Urinary 
Incontinence, Stress) or (Urinary Stress Incontinence) or 
(Incontinence, Urinary Stress) or (Stress Incontinence, Urinary) or 
(Urinary Incontinence, Urge) or (Urinary Reflex Incontinence) or 
(Incontinence, Urinary Reflex) or (Urinary Urge Incontinence) or 
(Urge Incontinence) or (Incontinence, Urge) or (Nocturnal Enuresis) 
or (Nighttime Urinary Incontinence) or (Incontinence, Nighttime 
Urinary) or (Urinary Incontinence, Nighttime) or (Diurnal Enuresis) 
or (Daytime Urinary Incontinence) or (Incontinence, Daytime 
Urinary) or (Urinary Incontinence, Daytime) or (Neurogenic Urinary 
Bladder) or (Bladder, Neurogenic) or (Neurogenic Bladder) or (Urinary 
Bladder Neurogenic Dysfunction) or (Neurogenic Dysfunction of 
the Urinary Bladder) or (Neurogenic Urinary Bladder Disorder) or 
(Neuropathic Bladder) or (Urinary Bladder Disorder, Neurogenic) or 
(Bladder Disorder, Neurogenic) or (Neurogenic Bladder Disorders) 
or (Neurogenic Bladder Disorder) or (Urinary Bladder Neurogenesis) 
or (Neurogenesis, Urinary Bladder) or (Bladder Neurogenesis) or 
(Neurogenesis, Bladder) or (Neurogenic Urinary Bladder, Atonic) 
or (Neurogenic Bladder, Atonic) or (Atonic Neurogenic Bladder) or 
(Neurogenic Urinary Bladder, Spastic) or (Neurogenic Bladder, Spastic) 
or (Spastic Neurogenic Bladder) or (Neurogenic Urinary Bladder, 
Uninhibited) or (Neurogenic Bladder, Uninhibited) or (Uninhibited 
Neurogenic Bladder) or (Overactive Bladder) or (Overactive Urinary 
Bladder) or (Bladder, Overactive) or (Overactive Detrusor) or (Detrusor, 
Overactive) or (Overactive Detrusor Function) or (Detrusor Function, 
Overactive):ti,ab,kw (Word variations have been searched)
#3 #1 or #2 or #3 or #4 or #5 or #6
Filter: in Cochrane Reviews
Table 1. Search strategy
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full texts, 20 reviews11–30 were found to fulfill our inclusion crite-
ria and were included for qualitative synthesis.
Reviews included 
In the following section, we present a brief individual summary of 
each review included, according to the intervention assessed. 
For  details about the characteristics of the interventions, com-
parisons, outcomes and quality of evidence,31 see Table 2.
Pharmacological interventions
Adrenergic agonists 
This review11 aimed to assess the effects of adrenergic agonists for 
stress urinary incontinence (SUI), since these medications may 
improve bladder neck muscle contraction. The SR included 22 ran-
domized clinical trials (RCTs) (1,099 participants) that assessed 
phenylpropanolamine, midodrine, norepinephrine, clenbuterol, 
Pharmacological treatments
Intervention Comparators Urinary incontinence type Main findings GRADE31
Adrenergic agonists11 Placebo Stress
Adrenergic agonists seem to be better for:
• reducing the number of pad changes
• reducing incontinence episodes
• improving symptoms
Not assessed
Estrogen 
(systemic or local)12
Placebo Not specified
Favors placebo: Low
• Improvement of urinary incontinence (oral 
systemic estrogen) 
Low
No difference between groups: Moderate
• Urinary incontinence episodes over 24 hours 
• Women with urge incontinence  (systemic estrogens)
Low 
Favors estrogen: Moderate
• Women with urge incontinence  (local estrogen)
• Improvement of urinary incontinence (local estrogen)
• Improvement of urinary incontinence (local 
systemic estrogen)
Very low
SNRI 13
Placebo 
and PFMT
Stress
Favors SNRI:
• Higher proportion of participants with symptom 
improvement 
Favors control group:
• Lower rate of adverse events 
No difference between groups:
• Rate of cure
Not assessed
Adding biofeedback 
and feedback to 
other therapies14
Other therapies 
without 
biofeedback
Urge and mixed
Favors addition of biofeedback:
• Women’s perception of change in incontinence
• Women’s satisfaction 
Not assessed
Bladder training15
Pharmacological 
therapy, PFMT, 
biofeedback
Not specified
Favors bladder training:
• Better patient perception of cure
• Improvement of quality of life
Not assessed
Habit retraining16 No intervention Not specified No evidence available Not assessed
Lifestyle 
interventions17
Any other 
intervention
Not specified
Favors weight loss program:
• Patient’s subjective impression of improvement
Low
No difference between groups: Low
• Cure rates
• Frequency of incontinence episodes per week  
Very low
Prompted voiding18
No intervention 
or other 
behavioral 
intervention
Not specified
Favors prompted voiding:
Lower proportion of hourly checks that were wet
Fewer incontinent episodes
Not assessed
Timed voiding19
Pharmacological 
and behavioral 
therapies
Not specified No evidence available Not assessed
Absorbent products20
Other absorbent 
product
Not specified No evidence available Not assessed
Table 2. Characteristics of interventions, comparisons, outcomes and quality of evidence
Continues...
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Pharmacological treatments
Intervention Comparators Urinary incontinence type Main findings GRADE31
Acupuncture21
Pharmacological 
intervention 
(midodrine)
Stress
Favors acupuncture:
• Improvement of symptoms (subjective assessment)
No difference between groups:
• Cure rate
Not assessed
Mechanical devices22
No intervention, 
sham or other 
interventions
Not specified No evidence available Not assessed
Transurethral 
radiofrequency 
collagen 
denaturation23
Sham Not specified
No difference between groups:
• Quality of life
• Adverse events
• Urinary tract infection
Low
Any intervention24
Different 
intervention, no 
intervention or 
placebo
Urinary incontinence after 
stroke
Favors meclofenoxate (compared with placebo):
• Reduction of urinary symptom perception 
Favors acupuncture (compared with usual care/no 
intervention):
• Reduction in number of participants with incontinence
Not assessed
Urethral injection 
therapy25
Conservative 
or surgical 
management
Not specified
Favors injection:
• Improvement of incontinence 
• Quality of life 
(compared with conservative treatment)
Favors surgical treatment:
• Symptom improvement 
Not assessed
Weighted 
vaginal cones26
No treatment, 
PFMT, 
electrostimulation
Stress
Favors vaginal cones:
• Incontinence cure (compared with no treatment)
No difference between groups:
• Subjective cure assessment (compared with pelvic 
exercises or electrostimulation) 
Not assessed
PFMT plus
active
treatment27 
Active 
treatment alone
Stress, urge and mixed
• PFMT plus electrical stimulation versus electrical 
stimulation alone: no difference between groups regarding 
cure or improvement of symptoms
Low 
• PFMT plus heat/steam-generating sheet versus heat/
steam sheet alone: benefit of PFMT regarding cure and 
symptom improvement 
Moderate
• PFMT plus vaginal cones versus vaginal cones alone: no 
difference between groups
Very low
PFMT
No treatment, 
placebo or sham28
Stress, urge and mixed
Favors PFMT:
• Cure at end of follow-up
High
• Symptom improvement Moderate
Different 
approaches 
for PFMT29
Stress, urge and mixed
• Perception of improvement: better with supervision twice 
a week than once a week
No difference between groups:
• Perception of improvement: no difference between group 
supervision and individual supervision, or between direct 
and indirect methods of PFMT
Not assessed
PFMT in
antenatal and
postnatal
period30
No treatment, 
different 
approaches for 
PFMT in antenatal 
and postnatal 
period30
Not specified
Favors intensive antenatal PFMT: 
• Incidence of incontinence over first six months after 
delivery (prevention)
Favors intensive postnatal PFMT: 
• Rate of incontinence 12 months after delivery (treatment)
Not assessed
PFMT = pelvic floor muscle training; SNRI = serotonin-noradrenaline reuptake inhibitor.
*GRADE (Grading of Recommendations Assessment, Development and Evaluation) is a tool for assessing the quality of the body of evidence. Outcomes are 
classified as presenting high quality of evidence (high confidence that the estimated effect is close to the true effect); moderate quality of evidence (very likely 
that the estimated effect is close to the real effect, but there is a possibility that it is not); low quality of evidence (confidence in the estimated effect is limited); 
or very low quality of evidence (the true effect is likely to be substantially different from the estimated effect).
Table 2. Continuation
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terbutaline, phenylpropanolamine hydrochloride/diphenylpyraline 
hydrochloride and dabuzalgron (Ro 115-1240). The evidence was 
very limited and no data were pooled for primary outcomes. The 
results from single RCTs showed some possible effects from use of 
adrenergic agonists for improving symptoms and reducing the num-
ber of pad changes. However, these results were poorly reported and 
some important data were missing. Additionally, there is not enough 
evidence for assessing the effects of these drugs when compared with 
or combined with other treatments, and hence further larger trials 
with better quality are needed, to provide stronger evidence. The lat-
est version of this review was published in 2010 and it was declared 
to be stable considering that some drugs were no longer used and 
that no new trials were expected. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001842.
pub2/abstract.
Estrogens
This review12 evaluated the effects of estrogens (local or systemic) 
on post-menopausal women with urinary incontinence (UI), 
and included 34 RCTs (19,676 participants). From the compari-
son of estrogen versus placebo/no treatment, the following find-
ings were observed:
• Number of participants with no improvement of urinary incon-
tinence: use of oral systemic estrogens gave rise to a higher num-
ber of participants with no improvement (risk ratio [RR] 1.32; 
95% confidence interval [CI] 1.17 to 1.48; six RCTs; 6,151 par-
ticipants; low quality of evidence), while use of local estrogens 
gave rise to a lower number of participants with no improve-
ment (RR 0.74; 95% CI 0.64 to 0.86; four RCTs; 213 partici-
pants; very low quality of  evidence).
• Episodes of urinary incontinence over 24 hours: no difference 
between the groups (mean difference [MD] 0.54; 95% CI -0.5 
to 1.57; two RCTs; 82 participants; low quality of evidence). 
• Women with urge incontinence: no difference between use of 
systemic estrogens and placebo (RR 1.05; 95% CI 0.83 to 1.33; 
two RCTs; 89 participants; moderate quality of evidence), but 
lower rate with local estrogens than with placebo (RR 0.38; 
95% CI 0.15 to 0.99; two RCTS; 90 participants; moderate 
quality of evidence).
• Women with adverse events: higher rate with use of systemic 
estrogens (RR 13; 95% CI 1.87 to 90.21; one RCT; 40 partici-
pants; low quality of evidence). No difference in adverse events 
was found with use of local estrogens, compared with placebo 
(RR 1.33; 95% CI 0.32 to 5.61; two studies; 144 participants; 
moderate quality of evidence).
The authors concluded that local estrogen treatment may 
improve UI, but that there was only limited evidence regarding 
its effects in the post-treatment period and over the long term. 
However, it was observed that systemic estrogen treatment might 
worsen incontinence. The data were insufficient to identify the opti-
mal estrogen type and dose, and there was no direct evidence for 
comparing routes of administration. The risk of endometrial and 
breast cancer after long-term use of systemic estrogen suggested 
that this treatment should only be administered for limited peri-
ods, especially among women with an intact uterus. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001405.
pub3/abstract.
Serotonin-noradrenaline reuptake inhibitors (SNRIs) 
This review13 assessed the effects of a SNRI (duloxetine) for 
treating women who presented UI. Ten RCTs were included 
(n = 3,944), and these compared duloxetine with placebo and/
or pelvic floor muscle training over periods of three to 12 weeks. 
The main results were:
• Number of participants with urinary incontinence at the end 
of the follow-up: no benefits from use of duloxetine 80 mg/
day (RR 0.97; 95% CI 0.93 to 1.00; three RCTs; 1,396 partic-
ipants), 40 mg/day (RR 0.89; 95% CI 0.79 to 1.01; one RCT; 
255 participants) and 20 mg/day (RR 0.99; 95% CI 0.89 to 1.09; 
one RCT; 260 participants).
• Number of participants without improvement during treatment: 
lower through use of duloxetine 80 mg/day (RR 0.74; 95% CI 
0.68 to 0.81; four RCTs; 1,733 participants), 40 mg/day (RR 0.64; 
95% CI 0.45 to 0.90; one RCT; 67 participants) and 20 mg/day 
(RR 0.55; 95% CI 0.40 to 0.75; two RCTs; 160 participants).
• Adverse events: more frequent through use of duloxetine 80 mg/
day (RR 1.25; 95% CI 1.14 to 1.36; six RCTs; 1,879 participants).
These results showed that duloxetine could improve symptoms 
but failed to show any objective improvements in cure rate. The 
number of participants presenting adverse events was higher in 
the duloxetine group. Further studies comparing duloxetine and 
other SNRIs with other treatments are needed in order to reach 
additional conclusions.
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004742.
pub2/abstract.
Behavioral methods
Biofeedback
This review14 assessed the effects of pelvic exercises using differ-
ent types of feedback and biofeedback among women with urge 
incontinence and mixed urinary incontinence. Twenty-four tri-
als (n = 1,583) were included and the main results were:
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• Pelvic floor muscle training (PFMT) with biofeedback versus 
PFMT alone: PFMT with biofeedback was statistically sig-
nificantly better for improving women’s perception of change 
in incontinence (RR 0.75; 95% CI 0.66 to 0.86; seven RCTs; 
520 participants) and women’s satisfaction (RR 0.65; 95% CI 
0.46 to 0.90; three RCTs; 294 participants). There was also a 
marginally significant result regarding reduction of the num-
ber of leakage episodes (MD -0.12; 95% CI -0.22 to -0.01; 
eight RCTs; 532 participants), but this result might not be 
clinically relevant.
• PFMT with feedback versus PFMT alone: The group that 
received feedback had better perception of change in incon-
tinence (RR 0.53; 95% CI 0.37 to 0.78; one RCT; 122 partici-
pants) and greater satisfaction (RR 0.33; 95% CI 0.16 to 0.66; 
one RCT; 166 participants).
Other comparisons were made, but the effects of biofeed-
back/feedback interventions could not be individually interpreted. 
The authors of this SR concluded that feedback or biofeedback 
might provide benefits when added to PFMT in treating urinary 
incontinence. However, no assessment of quality of evidence was 
made and no data for safety assessment were provided in the 
RCTs included. 
For further details, refer to the original abstract, available 
from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD009252/abstract.
Bladder training
This review15 assessed bladder training, defined as a behavioral 
technique in which the patient is trained to resist the first urge to 
urinate and to refrain from urinating until a planned scheduled 
time. Eight RCTs (n = 858, predominantly female) were included 
and the main findings were:
a) Bladder training versus oxybutynin: 
• Patient’s perception of cure at six months: better in 
bladder training group (RR 1.69; 95% CI 1.21 to 2.34; 
one RCT; 81 participants).
• Quality of life (general physical measurement): better in 
bladder training group (weighted mean difference [WMD] 
9.00; 95% CI 1.64 to 16.36; one RCT; 57 participants).
b) Bladder training versus imipramine plus flavoxate:
• Patient’s perception of cure immediately after treatment: 
better in bladder training group (RR 1.50; 95% CI 1.02 to 
2.21; one RCT; 50 participants).
c) Bladder training plus pelvic exercises plus biofeedback versus 
pelvic exercises plus biofeedback:
• Patient’s perception of improvement: better with blad-
der training (RR 1.18; 95% CI 1.01 to 1.39; one RCT; 
125 participants).
All the results of this systematic review were based on poorly 
reported low-quality RCTs with small sample sizes. The main out-
comes were subjective and not pre-specified. Therefore, conclusions 
regarding the effectiveness and safety of bladder training must await 
further studies with good methodological and reporting qualities. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001308.
pub2/abstract.
Habit retraining
This review16 assessed the effects of habit retraining, which con-
sists of assistance for toileting provided by a caregiver, with the 
aim of management of UI. Four RCTs (n = 378) were included, 
and most of the participants were elderly women who were phys-
ically and/or cognitively impaired, and dependent on caregivers. 
All the RCTs had important methodological limitations and the 
sparseness of the reported data and the clinical diversity between 
the studies prevented any quantitative synthesis. Until further 
studies are available, no judgment regarding the effectiveness and 
safety of habit retraining can be made. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002801.
pub2/full.
Lifestyle interventions
This review17 assessed the effects of low-cost, non-invasive life-
style interventions, such as
• dietary changes 
• weight loss
• smoking cessation
• physical activity and
• fluid intake in relation to management of UI. Eleven RCTs 
were included (n = 5,974; mostly female participants).
The following results were found regarding comparison of weight 
loss programs versus any other intervention:
• Patient’s subjective impression of improvement: better in the 
weight loss program group (RR 1.40; 95% CI 1.14 to 1.71; 
one RCT; 304 participants; low quality of evidence).
• Cure rates: no difference between groups (RR 1.11; 95% CI 0.91 
to 1.37; one RCT; 738 participants; low quality of evidence).
• Frequency of incontinence episodes per week:  no difference 
between groups (RR 0.88; 95% CI 0.78 to 1.00; one RCT; 
2,739 participants, very low quality of evidence).
All the trials included were judged to present high risk of bias. 
Taking into account the quality of the body of evidence relating to 
weight loss programs and the lack of high quality RCTs, no solid 
conclusion can be drawn until new studies are available. 
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For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003505.
pub5/abstract.
Prompted voiding
This review18 assessed the effects of prompted voiding (a behavioral 
technique in which the patients receive verbal toilet reminders) for 
elderly people with UI. Nine RCTs were included (n = 674, the major-
ity of whom were women). The prompted voiding group presented 
better results for the following outcomes:
• Reduction of the proportion of hourly checks that found wet-
ness (mean difference (MD) 12%; 95% CI -18.79% to -5.21%; 
one RCT; 148 participants).
• Fewer episodes of incontinence over 24 hours (MD -0.92; 95% 
CI -1.32 to -0.53; two RCTs; 257 participants). 
No statistical difference between the groups were found regard-
ing the number of people with no improvement in wet episodes 
(OR 0.60; CI 95% 0.29 to 1.26; one RCT; 133 participants). Many of 
the RCTs included did not provided minimum statistical data for 
analysis. Also, the clinical outcomes assessed in these RCTs were 
too diverse and poorly reported. The small sample size and poor 
methodological quality of the RCTs were an obstacle to drawing 
any recommendations for practice. Further studies investigating 
prompted voiding are needed in order to evaluate the safety and 
effectiveness of this intervention. 
For further details, refer to the original abstract, available 
from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD002113/abstract.
Timed voiding
This review19 evaluated the effects of timed voiding for manage-
ment of UI among elderly women. Two RCTs of poor method-
ological quality (n = 298) were included and these assessed the 
effects of timed voiding combined with the usual care (estrogens, 
propantheline and flavoxate). Therefore, the extent of the effects 
of timed voiding alone could not be assessed. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002802.
pub2/abstract.
Miscellaneous interventions
Absorbent products
This review20 evaluated the effectiveness of different types 
of absorbent products for moderate-to-heavy incontinence. 
Two  RCTs were included (n = 185). Fourteen comparisons of 
absorbent products were made, including disposable insert pads, 
disposable diapers, T-shaped diapers, disposable pull-ups and 
washable diapers. The results were sparse and based on only two 
low-quality RCTs. For most of the comparisons, no difference in 
the effects was found. Furthermore, for those in which a differ-
ence was found, the low quality of the studies precluded any prac-
tical recommendation. 
For further details, refer to the original abstract, available 
from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD007408/abstract. 
Acupuncture
This review21 evaluated the benefits and harms of acupuncture 
among adults with UI. It included one RCT (n = 60 women) that 
compared acupuncture versus midodrine:
• Improvement of symptoms (subjective assessment): better 
with acupuncture (RR 2.20; 95% CI 1.27 to 3.81; one RCT; 
60 participants). 
• Cure rate: no difference between groups (RR 2.00; 95% CI 0.40 
to 10.11; one RCT; 60 participants).
Because this review included only one small head-to-head study 
with low methodological quality and poor reporting, no conclu-
sions can be reached regarding the efficacy and safety of acupunc-
ture among UI patients. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009408.
pub2/abstract.
Mechanical devices
The objective of this review22 was to assess the use of mechani-
cal devices for management of adult female UI. Eight RCTs were 
included (n = 787), but no solid conclusions could be drawn 
because of the lack of reporting and lack of relevant clinical out-
come assessment. The RCTs included were poorly reported and no 
meta-analysis could be performed because of the scarcity and het-
erogeneous nature of the data. Until further good methodological 
quality RCTs are published, the uncertainty regarding the effects 
of mechanical devices in patients with UI will remain unresolved. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001756.
pub6/abstract.
Transurethral radiofrequency collagen denaturation (TRCD)
This review23 evaluated the effects of TRCD in relation to incon-
tinence among women. TRCD is a minimally invasive device-
based intervention in which a low-temperature heat is applied via 
the urethra. One RCT (n = 142) comparing TRCD with a sham 
group found the following:
• Quality of life: no difference between groups (RR 1.11; 95% CI 
0.77 to 1.62; one RCT; 142 participants; low quality of evidence)
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• Adverse events: no difference between groups (RR 1.36; 95% CI 
0.63 to 2.93; one RCT; 173 participants, low quality of evidence)
• Urinary tract infection: no difference between groups (RR 0.95; 
CI 95% 0.24 to 3.86; one RCT; 173 participants; low quality 
of evidence).
The authors concluded that there was insufficient evidence to 
be able to state that TRCD improves quality of life among patients 
with UI. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010217.
pub2/abstract.
Treatment of UI after stroke 
This review24 evaluated different treatments for UI after stroke 
and included 12 RCTs (n = 724 participants). The interven-
tions considered were the following: behavioral interven-
tions (three RCTs), specialized professional input interventions 
(two RCTs), complementary therapy interventions (three RCTs) 
and pharmacotherapy and hormonal interventions (three RCTs). 
Most of the RCTs included had small sample sizes and were 
poorly reported. The main findings were:
• Meclofenoxate versus placebo: reduction in the perception of 
urinary symptoms through use of meclofenoxate (RR 0.33; 
95% CI 0.18 to 0.62; one RCT; 80 participants).
• Acupuncture versus usual care/no intervention: reduction 
in the number of participants with incontinence after treat-
ment in the acupuncture group (RR 0.44; 95% CI 0.23 to 0.86; 
three RCTs; 219 participants).
The authors concluded that there was insufficient evidence to 
guide UI management after stroke. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004462.
pub3/abstract.
Urethral injection therapy
This review25 evaluated the efficacy and safety of injections of 
periurethral or transurethral bulking agents that had the aim 
of creating artificial cushioning in the area around the urethra. 
It included 14 RCTs (n = 2,004 women) and the main results were:
• Injection versus conservative treatment: the injection 
treatment group had a higher number of participants with 
improvement of continence than did the conservative 
treatment group (RR 0.70; 95% CI 0.52 to 0.94; one RCT; 
45 participants) and it achieved a statistically significant 
improvement of quality of life (MD 0.54; 95% CI 0.16 to 
0.92; one RCT; 45 participants).
• Injection versus surgical management: the surgical group had 
higher rates of symptom improvement in two trials: RR 4.77; 
95% CI 1.96 to 11.64; one RCT; 45 participants in one study; 
and RR 1.69; 95% CI 1.02 to 2.79; one RCT; 54 participants in 
the other study.
The results from the remaining RCTs included were poorly 
reported and no data could be pooled because of the lack of rel-
evant outcome results and because of the heterogeneity between 
studies. Until further high-quality studies are available, the bene-
fits of urethral injection therapy in patients with urinary inconti-
nence will remain a matter that needs to be resolved.
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003881.
pub4/abstract.
Weighted vaginal cones
This review26 evaluated the efficacy and safety of use of 
weighted vaginal cones for women with urinary incontinence 
and it included 23 RCTs (n = 1,806). The following results 
were found: 
• Weighted vaginal cones versus no treatment: the intervention 
group had a lower number of patients with urinary inconti-
nence at the end of the follow-up (RR 0.84; 95% CI 0.76 to 
0.94; four RCTs; 375 participants). 
• Weighted vaginal cones versus pelvic exercises: no difference 
between the groups regarding subjective assessment of cure 
(RR 1.01; 95% CI 0.91 to 1.13; five RCTs; 338 participants).
• Weighted vaginal cones versus electrostimulation: no difference 
between the groups regarding subjective assessment of cure 
(RR 1.26; 95% CI 0.85 to 1.87; three RCTs; 151 participants).
The authors concluded that these findings suggested that cones 
were a better option than no treatment. However, no assessment of 
the quality of the body of evidence was made. More high-quality 
trials are necessary in order to fully evaluate the possible benefits 
and adverse events of use of weighted cones for treatment of uri-
nary incontinence, preferably with larger sample sizes and using 
standard relevant outcomes.
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002114.
pub2/abstract.
Pelvic floor muscle training (PFMT) interventions 
Four reviews27–30 assessed the efficacy and safety of PFMT for 
management of UI (stress, urge and mixed) in women.
One review27 compared PFMT combined with active treat-
ment versus the same active treatment alone, and included 13 trials 
(n = 1,164). The key outcomes considered by the review authors 
were not assessed in the majority of the RCTs included. The main 
results reported were:
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• PFMT plus electrical stimulation versus electrical stimulation 
alone: no difference between groups regarding cure or improve-
ment of symptoms (RR 2.06; 95% CI 0.79 to 5.38; two RCTs; 
56 participants; very low quality of evidence).
• PFMT plus heat and steam-generating sheet versus heat and 
steam-generating sheet alone: the group that received PFMT 
had higher likelihood of participants presenting cure or symp-
tom improvement (RR 2.38; 95% CI 1.19 to 4.73; one RCT; 74 
participants; moderate quality of evidence).
• PFMT plus vaginal cones versus vaginal cones alone: no 
difference between groups (RR 1.27; 95% CI 0.94 to 1.71; 
one RCT; 34 participants; very low quality of evidence).
The adverse events were only evaluated in one RCT in which 
PFMT in combination with drug therapy was assessed, and this 
did not find any statistical difference (RR 0.84; 95% CI 0.45 to 1.60; 
one RCT; 162 participants; very low quality of evidence). In the 
light of these findings, the authors concluded that there was insuf-
ficient evidence to state what the effects of addition of PFMT to 
treatments for urinary incontinence were. 
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010551.
pub3/abstract.
The second review28 included 21 RCTs (n = 1,281 partici-
pants) that compared PFMT with no treatment, placebo or sham. 
The main results were:
• Cure at the end of the follow-up: higher likelihood in the PFMT 
group (RR 8.38; 95% CI 3.68 to 19.07; four RCTs; 165 partic-
ipants; high quality of evidence).
• Symptom improvement: higher likelihood in the PFMT group 
(RR 17.33; 95% CI 4.31 to 69.64; two RCTs; 121 participants; 
moderate quality of evidence).
The authors concluded that these findings supported a rec-
ommendation to use PFMT as first-line conservative therapy for 
women with urinary incontinence.  
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005654.
pub3/abstract.
Other comparisons were made, but the data were sparse and 
based on low-quality RCTs. Moreover, there was no assessment of 
the quality of the body of evidence for any comparison. The authors 
concluded that currently there was insufficient evidence to make any 
strong recommendations about the best approach to use for PFMT. 
For further details, refer to the original abstract, available 
from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD009508/abstract.
The fourth review30 assessed the effects of PFMT for preven-
tion and treatment of UI among antenatal and postnatal women. 
Twenty-two RCTs (n = 8,485) were included and the main find-
ings were:
• Incidence of incontinence over the first six months after deliv-
ery (prevention): lower likelihood among pregnant women with 
intensive antenatal PFMT than among those with postnatal 
PFMT (RR 0.71; 95% CI 0.54 to 0.95; five RCTs; 673 participants).
• Rate of incontinence 12 months after delivery (treatment): 
no difference in likelihood between pregnant women with 
intensive postnatal PFMT and those who received intensive 
antenatal PFMT (RR 0.60; 95% CI 0.35 to 1.03; three RCTs).
The authors concluded that there was some evidence to sup-
port the use of PFMT among women who were having their first 
baby, to prevent UI over the first six months after delivery. However, 
there was no appraisal of the quality of the evidence, and the clini-
cal and methodological heterogeneity among the studies included 
prevented other pooled analyses.  
For further details, refer to the original abstract, available from: 
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007471.
pub2/abstract.
DISCUSSION
This review included 20 Cochrane systematic reviews that 
assessed non-surgical interventions for women with urinary 
incontinence. The studies included evaluated pharmacologi-
cal interventions (three SRs), behavioral interventions (six SRs), 
miscellaneous interventions (seven SRs) and pelvic floor muscle 
training interventions (four SRs). 
Despite the considerable numbers of studies included in many 
of these SRs, most of them were poorly reported with low meth-
odological quality, which compromised confidence in the data 
synthesis. However, the quality of the body of evidence was only 
assessed in five SRs.12,17,23,27,28 Since the publication of the GRADE 
initiative,31 evaluation of the quality of the evidence synthetized 
has become recommended and, for further updates, this needs 
to be a priority.31 
Regarding the clinical implications, the only systematic reviews 
that presented moderate to high quality of evidence were those 
relating to use of pelvic floor muscle training among women with 
urinary incontinence. On the other hand, the quality of evidence 
reported was very low to moderate in relation to use of estrogen for 
treating and preventing urinary incontinence. Moreover, the out-
comes reported from all other interventions presented very low to 
low quality of evidence. The results presented in Table 2 may pro-
vide some guidance for using some of the interventions evaluated 
in this overview of systematic reviews, but most of the findings 
may change through future studies.
Regarding the implications for further research, our results sug-
gest that it is important to plan and conduct randomized controlled 
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trials assessing non-pharmacological interventions for women with 
urinary incontinence strictly in accordance with rigorous pro-
tocols. The trial protocols need to be published before the study 
begins and the results need to be presented in accordance with the 
CONSORT guidelines.32
CONCLUSION
This review included 20 Cochrane systematic reviews that pro-
vided evidence ranging in quality from unknown to high, in rela-
tion to non-pharmacological interventions for patients with uri-
nary incontinence. Moderate to high quality of evidence favoring 
use of pelvic floor muscle training among women with urinary 
incontinence was found. To establish solid conclusions for all the 
other comparisons, further studies of good methodological qual-
ity are needed.
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